UNSPSC 51294417: Aripiprazole lauroxil

This classification denotes an antipsychotic agent C36H51Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B786J7A343, chemically known as (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl dodecanoate, but more generally known as aripiprazole lauroxil, which bears US NIH Compound Identifier 49831411. Most nations, for tariff and trade purposes, schedule aripiprazole lauroxil under HS 29337900 and SITC 51561.

As of Q4 2014, ARIPIPRAZOLE LAUROXIL remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCC(=O)OCN1C2CC(CCC2CCC1=O)OCCCCN3CCN(CC3)C4CCCC(C4CL)CL.

UNSPSC 51294417 Aripiprazole lauroxil, a Commodity code, shows no recent state and local procurement activity directly matching the pharmaceutical product specified. The three opportunities posted under this code between January and June 2026 involve naloxone and drug deactivation systems, a Texas HHS direct-to-manufacturer prescription program inquiry, and a multistate cooperative purchasing contract for generic pharmaceuticals and OTC products—none of which specifically solicit aripiprazole lauroxil or any named antipsychotic medication. The mismatch suggests the code may have been applied in error by the issuing bodies or that state and local demand for this specific formulation is currently not generating tagged solicitations.

The geographic activity recorded includes Florida (Seminole County), Texas (Texas Health and Human Services Commission), and Minnesota (MMCAP, serving Minnesota and Oregon). The issuing bodies range from county health departments to state health agencies and multistate cooperative purchasing vehicles. Seminole County's IFB60459723LAS, due July 26, 2023, sought naloxone and drug deactivation systems through quarterly deliveries; the Texas HHS RFI HHS0017013 (due April 3, 2026) explored direct-to-manufacturer prescription programs without specifying products; and MMCAP's S1070000015802 RFP (due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers with an effective date of July 1, 2026. Because the recent opportunities do not address aripiprazole lauroxil specifically, no meaningful market signal exists under this code in current state and local procurement.